AKBA – akebia therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Form SCHEDULE 13G/A Akebia Therapeutics, Filed by: Satter Muneer A
Form 8-K Akebia Therapeutics, For: Feb 03
Form 4 Akebia Therapeutics, For: Jan 31 Filed by: Butler John P.
Form 4 Akebia Therapeutics, For: Jan 31 Filed by: Burke Steven Keith
Form 4 Akebia Therapeutics, For: Jan 31 Filed by: Grund Nicholas
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.